Bob Kaplan Joins Clinical Trials Solutions Firm

Bob Kaplan Joins Clinical Trials Solutions Firm

Baltimore, Md. - January 14, 2010 - Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today it has hired Robert E. Kaplan, MHA as chief information officer. As CIO, Bob Kaplan will be the head of information technology within C-TASC as well as oversee the development of the company's clinical trial management system (CTMS) software, scheduled for public release in 2010.

Kaplan has more than 16 years of experience in healthcare technology and specializes in designing technology infrastructures. He joins C-TASC from the Iowa Foundation for Medical Care where he had served as vice president of information systems and CIO since 2007. Previously, he was vice president and CIO of the National Committee for Quality Assurance (NCQA) from 2003-2007 and prior to that he worked as CIO of WebMD from 2001-2003. Bob holds a master's degree in health care administration from George Washington University and performed his administrative residency at Johns Hopkins Hospital.

For 20 years, C-TASC has specialized in supporting best practices management of clinical trials and studies for government, university and private organizations. The company has grown rapidly in the last three years, nearly doubling its revenue and number of employees since 2007. In that time, it has added professional consultation in all areas of clinical trial management to its offered services, incorporated a proprietary Web-based software system for clinical trials management and developed a relationship with the Food and Drug Administration to convert legacy data into the new standard SDTM format. In 2010, C-TASC plans to release its StudyCTMS product suite to the public to enable investigators to efficiently and affordably conduct small- and medium-sized clinical trials that produce FDA-quality data.

"Bob has an impressive track record of creating IT systems that support large, multi-million dollar companies in the healthcare industry," said Dr. Bruce Thompson, president, C-TASC. "Our staff has worked hard over the years to develop technology solutions that manage sophisticated clinical trials quickly and efficiently, and we feel that Bob is the right person to lead our efforts in the future."

"I am excited to work with the C-TASC staff and face the challenge of continuing to expand the business," said Kaplan. "Given its combination of expertise, services and tools, C-TASC has a unique opportunity to advance the clinical trials industry, and I am looking forward to enhancing its products and bringing them to the market."

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.